Haploidentical bone marrow transplantation with post-transplant cyclophosphamide/bendamustine in pediatric and young adult patients with hematologic malignancies
Haploidentical hematopoietic cell transplantation (haplo-HCT) has emerged as a safe and effective treatment for patients with hematologic malignancies. The most widely used approach, particularly in North America, is T-cell replete haplo-HCT with post-transplant cyclophosphamide (PT-CY) [1 –5]. While there have been numerous reports, of haplo-HCT with PT-CY in adults, there have been very limited primarily pediatric publications to date [6–8]. Jaiswal et al. reported on the use of PT-CY following a chemotherapy based myeloablative conditioning (MAC) regimen and unmanipulated perip heral blood hematopoietic cell transplant in pediatric leukemia patients in India [7].Berger et al.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Emmanuel Katsanis, Lauren N. Sapp, Nicole Varner, Shannon Koza, Baldassarre Stea, Yi Zeng Source Type: research
More News: Biology | Bone Marrow Transplant | Cancer & Oncology | Chemotherapy | Hematology | India Health | Leukemia | Pediatrics | Transplants | Treanda